98 related articles for article (PubMed ID: 10321502)
1. Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Katsumata N; Watanabe T; Tominaga T; Ogawa M; Adachi I; Enomoto K; Kajiwara T; Kusama M; Yamada Y; Abe O
Cancer Chemother Pharmacol; 1999; 43(6):441-4. PubMed ID: 10321502
[TBL] [Abstract][Full Text] [Related]
2. MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Watanabe T; Narabayashi M; Haga S; Yamada Y; Kawamura E; Enomoto K; Kusama M; Kimura K; Adachi I; Abe O
Jpn J Clin Oncol; 1993 Aug; 23(4):246-9. PubMed ID: 8411738
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Kuratsu J; Arita N; Kurisu K; Uozumi T; Hayakawa T; Ushio Y
J Neurooncol; 1999 Apr; 42(2):177-81. PubMed ID: 10421076
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Kuratsu JI; Arita N; Kayama T; Kubo N; Mori T; Sawamura Y; Ushio Y
J Neurooncol; 2000 Jun; 48(2):145-9. PubMed ID: 11083079
[TBL] [Abstract][Full Text] [Related]
5. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
Kubota T; Suto A; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Jpn J Cancer Res; 1990 Aug; 81(8):827-33. PubMed ID: 2144515
[TBL] [Abstract][Full Text] [Related]
7. KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Clarke K; Basser RL; Underhill C; Mitchell P; Bartlett J; Cher L; Findlay M; Dalley D; Pell M; Byrne M; Geldard H; Hill JS; Maher D; Fox RM; Green MD; Kaye AH
J Clin Oncol; 1999 Aug; 17(8):2579-84. PubMed ID: 10561325
[TBL] [Abstract][Full Text] [Related]
8. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
9. [Phase I and pharmacokinetic study of KRN8602, a new morpholino anthracycline].
Tabata M; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nagamine D; Shinagawa K; Fukutani H; Hirano A; Mizunuma N
Gan To Kagaku Ryoho; 1989 Jul; 16(7):2361-6. PubMed ID: 2546503
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Clarke K; Basser RL; Maher D; Morgan DJ; Cebon J; Fox RM; Hill JS; Alt C; Bartlett J; Geldard H; Kaye AH; Green MD
J Clin Oncol; 1998 Jun; 16(6):2181-7. PubMed ID: 9626219
[TBL] [Abstract][Full Text] [Related]
11. [Phase I clinical study of MX2 (KRN 8602)].
Majima H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):359-64. PubMed ID: 2310202
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
13. [Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination].
Hiraoka A; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):93-9. PubMed ID: 9987504
[TBL] [Abstract][Full Text] [Related]
14. A phase II study employing combination regimens containing KRN8602 in drug-resistant acute myeloid leukemia and acute lymphoblastic leukemia. KRN8602 Leukemia Study Group.
Kishimoto Y; Sampi K; Kuraishi Y; Takemoto Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Anticancer Drugs; 1999 Mar; 10(3):267-73. PubMed ID: 10327031
[TBL] [Abstract][Full Text] [Related]
15. Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
Ebrahim el-Zayat AA; Izquierdo MA; Clark GM; Von Hoff DD
Invest New Drugs; 1995; 13(2):125-131. PubMed ID: 8617574
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
[TBL] [Abstract][Full Text] [Related]
17. Role of DNA-binding in the cytotoxicity of an anthracycline, R20X2 and its morpholino analog, MX2.
Komeshima N; Kawai H; Nakajima S; Watanabe M; Tsuruo T; Takeuchi T; Otake N
J Antibiot (Tokyo); 1989 Sep; 42(9):1424-9. PubMed ID: 2793595
[TBL] [Abstract][Full Text] [Related]
18. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
[TBL] [Abstract][Full Text] [Related]
19. The antitumor effect of MX2, a new morpholino anthracycline, against malignant glioma cell lines and its subcellular distribution.
Kabuto M; Kubota T; Kobayashi H; Nakagawa T; Kitai R
Neurosurgery; 1995 Sep; 37(3):471-6; discussion 476-7. PubMed ID: 7501112
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
